


# Enemsa Pharma

Clinical-stage biotech focused on identifying and developing first-in-class combination therapies, built around **icerguastat**, a de-risked Integrated Stress Response (ISR) modulator enabling **high-synergy combinations** with approved or late-stage treatments across multiple and high-value indications that monotherapies fail to reach.

## Icerguastat – Mechanism of Action

- PPP1R15A/PP1c phosphatase complex modulation
- NR2B-containing NMDAR modulation
- Reduction of mitochondrial ROS
- ➔ *Enhanced cellular stress resilience*



## Clinical Validation

- Phase 1 completed backbone asset
- ➔ *Favorable safety and tolerability*
- Exploratory Phase 2 in ALS completed
- ➔ *Target engagement demonstrated*
- ➔ *Biomarker improvements observed*

## Lead Partnering Programs

Icerguastat-based therapeutic combinations programs

| Combo                           | Indication       | Discovery | IND-Enabling | Phase 1 | Phase 2 |
|---------------------------------|------------------|-----------|--------------|---------|---------|
| Icerguastat + Riluzole (oral)   | ALS              |           |              |         |         |
| Icerguastat + Ambroxol (oral)   | PD-GBA1          |           |              |         |         |
| Icerguastat + SoC (Undisclosed) | Cardio-pulmonary |           |              |         |         |

Clinical-stage icerguastat assets available for licensing or partnership

| Mono               | Indication | Discovery | IND-Enabling | Phase 1 | Phase 2 |
|--------------------|------------|-----------|--------------|---------|---------|
| Icerguastat (oral) | CMT        |           |              |         |         |

## Platform Value

- First- or best-in-class combinations
- New IP opportunities
- Multi-indication expansion

## Partnering Opportunities

- Global licensing
- Co-development
- Strategic partnerships
- Investment